DELFI Diagnostics Supports Legislation for CMS to Review New Lung Cancer Liquid Biopsies
DELFI Diagnostics is supporting the recently introduced Lung Cancer Screening and Prevention Act (H.R. 6693).
Read MorePosted by Andy Lundin | Dec 13, 2023 | Lung Cancer |
DELFI Diagnostics is supporting the recently introduced Lung Cancer Screening and Prevention Act (H.R. 6693).
Read MorePosted by Andy Lundin | Dec 12, 2023 | Lung Cancer |
Liquid biopsies could predict which lung cancer patients are responding to immunotherapies or may develop immune-related side effects.
Read MorePosted by Andy Lundin | Dec 11, 2023 | Cancer, Digital Pathology |
Researchers at UT Southwestern Medical Center developed a novel AI model that analyzes the spatial arrangement of cells in tissue samples.
Read MorePosted by Andy Lundin | Dec 8, 2023 | Breast |
Exai Bio’s liquid biopsy platform can detect breast cancer at the earliest stages and the smallest tumor sizes using a standard blood sample.
Read MorePosted by Andy Lundin | Dec 5, 2023 | Cancer |
UCLA Researchers received $9.1 million in grant funding from the National Cancer Institute to advance liquid biopsy tech for cancer detection.
Read More